Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 4/20 | 0.51 |
| ▸ | DRD1 | P21728 | 6/20 | 0.44 |
| ▸ | DRD5 | P21918 | 5/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581148 | 0.82 | RYR2 (0.44) | RYR2DRD1DRD5DRD2DRD3 | |
| SCHEMBL3587517 | 0.74 | RYR2 (0.47) | RYR2DRD1DRD5DRD2DRD3 | |
| SCHEMBL3902560 | 0.69 | DRD1 (0.65) | RYR2DRD1DRD5DRD2DRD3 | |
| SCHEMBL6867681 | 0.68 | RYR2 (1.00) | RYR2NOTUM | |
| SCHEMBL3586567 | 0.68 | RYR2 (0.47) | RYR2DRD1DRD5DRD2DRD3 | |
| SCHEMBL26767768 | 0.67 | DRD1 (0.54) | RYR2DRD1DRD5DRD2DRD3 | |
| SCHEMBL29853433 | 0.67 | DRD1 (0.54) | RYR2DRD1DRD5DRD2DRD3 | |
| SCHEMBL12894412 | 0.67 | RYR2 (0.84) | RYR2CA2NOTUM | |
| SCHEMBL19865381 | 0.67 | RYR2 (0.56) | RYR2DRD1DRD5DRD2DRD3 | |
| SCHEMBL30422601 | 0.66 | GRIA2 (0.47) | RYR2DRD1DRD5DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190778-A1 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENTARSASAG (HU) | 2010-07-29 | — | — | US | disclosed |
| EP-2064197-A2 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | Egis Gyogyszergyar Nyilvánosan Múködó Részvénytársaság (HU) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008020256-A2 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | EGIS GYÓGYSZERGYÁR_Nyilvánosan Müködö Részvénytársaság (HU) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190778-A1 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | TDO2, DHODH, DHPS | RYR2 774/4885DRD1 103/4885DRD5 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.